Home・Список акций・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

20.01 2.25

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

19.32

Макс.

20.32

Ключевые показатели
By Trading Economics
Доход	25M -43M
Продажи	-3.6M 65M
Прибыль на акцию	-0.48
Рентабельность продаж	-65.788
Сотрудники	298
EBITDA	-16M -31M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+92.02% upside

Дивиденды
By Acuity
Следующий отчет о доходах	2 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-147M 1.7B
Предыдущая цена открытия	17.76
Предыдущая цена закрытия	20.01

Новостные настроения

By Acuity

80%

20%

315 / 340 Рейтинг в Healthcare

Syndax Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 авг. 2026 г., 19:36 UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

5 авг. 2026 г., 20:02 UTC

News

Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

4 авг. 2026 г., 23:11 UTC

News

Syndax Pharmaceuticals shares are lower in after-market hours following a second-quarter earnings miss, reporting a net loss of $49.4 million and revenue of $72.8 million.

3 авг. 2026 г., 19:16 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares are higher amid a broader market rally. The stock remains below its 20-day moving average and near the lower end of its one-month range.

31 июл. 2026 г., 20:06 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares declined after first-quarter results showed lower performance. Broader market pressures from rising yields and oil prices contributed to the decline.

30 июл. 2026 г., 17:06 UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

29 июл. 2026 г., 19:56 UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

28 июл. 2026 г., 20:51 UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

27 июл. 2026 г., 20:06 UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

24 июл. 2026 г., 19:52 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

22 июл. 2026 г., 19:06 UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Сравнение c конкурентами

Изменение цены

Syndax Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

92.02% рост

Прогноз на 12 месяцев

Средняя 38.25 USD 92.02%

Максимум 57 USD

Минимум 26 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для Syndax Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

9 ratings

Покупка

Удержание

Продажа

Основано на мнении 9 аналитиков, присваивавших рейтинги акциям Syndax Pharmaceuticals Inc – Данные за последние 3 месяца.

Настроения

By Acuity

315 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.